武田制药公布银屑病新药临床研究结果 每日一次口服方案有望实现皮损清除

中国网财经
Dec 18, 2025

中国网财经12月18日讯武田制药今日宣布,其针对中重度斑块状银屑病(PsO)成人患者的新一代、高选择性口服酪氨酸激酶2(TYK2)抑制剂Zasocitinib(TAK-279)在两项关键性3期、随机、多中心、双盲、安慰剂与活性对照研究中取得积极的主要结果。  研究显示,Zasocitinib在第16周显著优于安慰剂,达到共同主要终点,即静态临床医生整体评估(sPGA)评分为0或1的参与者比例均优于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10